Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03288298
Recruitment Status : Unknown
Verified September 2017 by Safaa Elbaz, Cairo University.
Recruitment status was:  Not yet recruiting
First Posted : September 20, 2017
Last Update Posted : September 20, 2017
Sponsor:
Information provided by (Responsible Party):
Safaa Elbaz, Cairo University

Brief Summary:
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line.

Condition or disease Intervention/treatment Phase
Tongue Neoplasms Carcinoma Drug: luteolin Drug: nano-luteolin Early Phase 1

Detailed Description:
This study is conducted to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than luteolin on tongue squamous cell carcinoma cell line. The primary outcome is apoptosis, while the secondary outcome is cell viability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study
Estimated Study Start Date : November 1, 2017
Estimated Primary Completion Date : September 1, 2018
Estimated Study Completion Date : April 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: luteolin
a natural extract derived flavinoids
Drug: luteolin
flavonoid natural extract
Other Name: 3',4',5,7-tetrahydroxyflavone

Active Comparator: nano-luteolin
nano-particles derived from a natural extract luteolin
Drug: nano-luteolin
nanoparticles of luteolin
Other Name: nanoluteolin




Primary Outcome Measures :
  1. gene expression of Caspase 3 to detect apoptosis [ Time Frame: 6 hours ]
    fold-changes


Secondary Outcome Measures :
  1. cell viability [ Time Frame: 6 hours ]
    micromolar



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Squamous cell carcinoma cell lines (OSCC, TSCC and HNSCC).
  • Luteolin 5,7,3',4'-tetrahydroxy-flavone (MeSH term).
  • Application of luteolin as a chemotherapeutic drug.

Exclusion Criteria:

  • Any cancer cell line other than OSCC, TSCC and HNSCC cell lines.
  • Luteolin glycosides.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03288298


Contacts
Layout table for location contacts
Contact: Safaa M. Baz, Masters 002 01119777824 drsafaaelbaz@gmail.com
Contact: Safa F. Abd El-Ghani, PhD 002 01005198010 drsafa.fathy@yahoo.com

Sponsors and Collaborators
Cairo University
Investigators
Layout table for investigator information
Study Chair: Ahmed Elkhadem, PhD Center for Evidence Based Dentistry
  Study Documents (Full-Text)

Documents provided by Safaa Elbaz, Cairo University:
Publications:
Layout table for additonal information
Responsible Party: Safaa Elbaz, Assistant Lecturer, Oral and Maxillofacial Pathology, BUE, Cairo University
ClinicalTrials.gov Identifier: NCT03288298    
Other Study ID Numbers: CEBD-CU-2017-09-23
First Posted: September 20, 2017    Key Record Dates
Last Update Posted: September 20, 2017
Last Verified: September 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Safaa Elbaz, Cairo University:
TSCC
OSCC
luteolin
nanoluteolin
nanotechnology
oral cancer
apoptosis
PCR
MTT
ELISA reader
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Tongue Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases
Tongue Diseases